iRadimed Corporation (NASDAQ:IRMD) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts have a “Moderate Buy” consensus on iRadimed, with two buy ratings, one strong-buy rating and two hold ratings. The average 12-month price target is $120, compared with the stock’s recent price of $92.50.
• iRadimed exceeded quarterly expectations, reporting $0.46 in EPS versus the $0.44 consensus and revenue of $20.47 million versus estimates of $20.35 million. The company issued fiscal 2026 EPS guidance of $2.09–$2.24.
• The company declared a quarterly dividend of $0.20 per share, equivalent to an annualized $0.80 payout and a 0.9% yield. Institutional investors own 92.34% of the stock, while insiders sold more than $1.25 million worth of shares over the past three months.

Shares of iRadimed Corporation (NASDAQ:IRMD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $120.00.

Several analysts have recently issued reports on IRMD shares. Weiss Ratings downgraded iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, August 3rd. Wall Street Zen cut iRadimed from a "buy" rating to a "hold" rating in a research report on Saturday.

iRadimed Stock Performance

Shares of NASDAQ IRMD opened at $92.50 on Monday. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of 51.68 and a beta of 0.90. The business has a 50 day simple moving average of $94.55 and a 200 day simple moving average of $95.35. iRadimed has a 52 week low of $67.84 and a 52 week high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. The firm had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts predict that iRadimed will post 1.52 EPS for the current year.

iRadimed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 14th. iRadimed's payout ratio is currently 44.69%.

Insider Activity at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the company's stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $87.51, for a total transaction of $437,550.00. Following the completion of the transaction, the chief executive officer directly owned 2,175,000 shares in the company, valued at $190,334,250. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 14,411 shares of company stock worth $1,253,921 in the last three months. 34.60% of the stock is owned by insiders.

Institutional Investors Weigh In On iRadimed

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in iRadimed in the 2nd quarter valued at approximately $92,485,000. T. Rowe Price Investment Management Inc. grew its holdings in shares of iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider's stock worth $24,893,000 after purchasing an additional 205,783 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of iRadimed during the 2nd quarter worth approximately $7,252,000. Goldman Sachs Group Inc. increased its position in shares of iRadimed by 37.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider's stock valued at $19,964,000 after purchasing an additional 55,426 shares during the period. Finally, Informed Momentum Co LLC bought a new stake in shares of iRadimed during the fourth quarter valued at approximately $5,361,000. Institutional investors and hedge funds own 92.34% of the company's stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source